ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1804

TNF-Like Protein 1A/Death Receptor 3 Pathway Regulates Osteoclastogenesis and Is Associated with Erosive Disease in Rheumatoid Arthritis

Fraser L. Collins1, Michael D. Stone2, Rhian Goodfellow3, Ernest Choy4, Edward C. Wang5 and Anwen S. Williams6, 1Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 2University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, 3Section of Rheumatology, Cardiff University, Cardiff, ENGLAND, United Kingdom, 4Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, 5Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 6Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: matrix metalloproteinase (MMP), osteoclastogenesis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Bone erosion is a characteristic feature of inflammatory arthritides, such as rheumatoid arthritis (RA). Death Receptor 3 (DR3) and its only known ligand TNF-like protein 1A (TL1A) have been identified as key regulators of osteoclastogenesis in murine models of arthritis (Bull MJ, Williams AS et.al. J.Exp.Med. 2008). We investigated the potential mechanisms by which the DR3/TL1A pathway orchestrates osteoclast (OC) formation in humans and assessed the impact of DR3 signalling upon bone pathology in RA.

Methods:

CD14+ monocytes were obtained from healthy females (n=8). Cells were cultured on ivory discs (with macrophage-colony-stimulating factor (M) and receptor activator of nuclear factor-κB ligand (R)) for 7, 10 and 14 days ± TL1A (10 and 100ng/ml). Osteoclastogenesis and area of disc resorbed were quantified. Levels of TNFα and MMP-9 were measured by ELISA. Serum samples were obtained from consenting normal human volunteers (n=12) and RA patients (n=36) attending outpatient clinic who fulfilled the ACR classification criteria.TL1A and TNFα were measured by ELISA. Ethical approval for this study was granted by the Bro-Taf Health Authority. All data is expressed as mean±SEM value.

Results:

A significant dose-dependent increase in osteoclastogenesis was observed after addition of exogenous TL1A (P<0.01; 2-way ANOVA) in our in vitro human system. Cell counts per mm2, at end-point, were comparable for each condition tested (M+R=480±49; M+R+TL1A-10=517±62 and M+R+TL1A-100=475±59). However, TL1A (100ng/ml) doubled the number of OC observed on each ivory disk (12±3; OC per mm2) when compared against controls (6.8±2; P<0.05). These OC were functionally active, evidenced by their capacity to resorb a bone substrate. TL1A (100ng/ml) induced a potent 5-fold increase in bone resorption (5.19±3%) over control cultures (1.33±0.43%, P<0.01); the effect was dose-dependent. This was accompanied by a significant (P<0.01; 2-way ANOVA) dose and time dependent elevation in bone-matrix degrading MMP-9 secretion. MMP-9(μg/ml) increased from 4.8±1.1 to 7.5±1 for controls versus TL1A (100ng/ml) activated cultures on day 14. These data reveal a new mechanism for DR3’s resorptive function in bone. This action was independent of TNFα ; the cytokine was not detected in any of culture conditions studied. In serum collected from RA patients, TL1A levels were significantly elevated (P<0.05) over normal healthy individuals (3.0±0.6 versus 0.2±0.2 ng/ml). Serum levels of TL1A were also significantly higher in RA (rheumatoid factor positive) patients with erosive disease over those who had no detectable radiographic changes at time of sampling (3.9±0.8 and 0.5±0.2 ng/ml). TNFα was not detected in any of the samples assayed.

Conclusion:

Our findings reveal TL1A to be a key regulator in osteoclastogenesis and imply that the TL1A/DR3 pathway contributes to osteoclast-driven bone pathology associated with RA.


Disclosure:

F. L. Collins,
None;

M. D. Stone,
None;

R. Goodfellow,
None;

E. Choy,
None;

E. C. Wang,
None;

A. S. Williams,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnf-like-protein-1adeath-receptor-3-pathway-regulates-osteoclastogenesis-and-is-associated-with-erosive-disease-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology